​

ANI Pharmaceuticals Ownership | Who Owns ANI Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

ANI Pharmaceuticals Ownership Summary

ANI Pharmaceuticals is owned by 101.87% institutional investors, 10.98% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 14.11% of ANIP shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 4.61% of its assets in ANI Pharmaceuticals shares.

ANIP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockANI Pharmaceuticals101.87%10.98%-12.85%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustrySpecialty & Generic Drug Manufacturers Stocks2774.71%11.85%-2686.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de2.74M14.11%$151.39M
Blackrock2.66M13.91%$169.17M
Vanguard group1.31M6.77%$72.66M
Millennium management1.00M5.17%$55.44M
State street737.29K3.80%$40.76M
Goldman sachs group699.62K3.61%$38.67M
Dimensional fund advisors lp685.73K3.53%$37.91M
Deep track capital, lp649.04K3.34%$35.88M
Global alpha capital management624.55K3.22%$34.53M
Ubs group594.81K3.07%$32.88M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Global alpha capital management624.55K2.51%$34.53M
Sio capital management160.05K2.49%$8.85M
Ranger investment management577.74K2.02%$31.94M
Deep track capital, lp649.04K1.34%$35.88M
Tang capital management317.50K1.16%$17.55M
Marathon capital management69.89K0.96%$3.86M
Stonepine capital management20.40K0.91%$1.13M
Soleus capital management205.29K0.71%$11.35M
Kings path partners19.42K0.46%$1.07M
Perkins capital management8.44K0.41%$466.62K

Top Buyers

HolderShares% AssetsChange
Millennium management1.00M0.03%473.10K
Ubs group594.81K0.01%308.32K
Abrdn237.97K0.02%237.97K
Sio capital management160.05K2.49%160.05K
Deep track capital, lp649.04K1.34%144.21K

Top Sellers

HolderShares% AssetsChange
Jpmorgan chase268.05K0.00%-286.79K
Woodline partners lp---156.49K
Tang capital management317.50K1.16%-132.50K
Nuveen asset management49.64K0.00%-132.38K
Brandywine global investment management---100.90K

New Positions

HolderShares% AssetsChangeValue
Abrdn237.97K0.02%237.97K$13.15M
Raymond james financial70.83K0.00%70.83K$3.92M
Canada pension plan investment board30.70K0.00%30.70K$1.70M
Stonepine capital management20.40K0.91%20.40K$1.13M
Graham capital management6.36K0.01%6.36K$351.47K

Sold Out

HolderChange
Mendota financial group-1.00
Financial gravity asset management-1.00
Harbour investments-1.00
Nelson, van denburg & campbell wealth management group-1.00
Elequin securities-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202522911.16%19,974,4243.61%1011.03%11011.11%7220.00%
Dec 31, 2024203-3.33%19,272,0261.94%991.05%98-21.60%5937.21%
Sep 30, 20242091.95%18,894,59324.90%971.55%12516.82%43-30.65%
Jun 30, 2024203-1.46%15,126,9587.17%791.45%105-2.78%6219.23%
Mar 31, 202420612.57%14,115,5553.76%731.44%10825.58%52-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF997.35K4.61%-616.00
Vanguard US Total Market Shares ETF588.25K2.73%-
Pacer US Small Cap Cash Cows 100 ETF549.63K2.62%-1.87K
Vanguard Total Stock Mkt Idx Inv539.45K2.49%37.16K
iShares Russell 2000 ETF470.85K2.17%231.00
Ranger Small Cap378.80K1.76%-5.63K
Delaware Ivy Small Cap Growth C336.40K1.60%-
CC&L Global Alpha - Series A342.50K1.58%8.00K
AZ InvestEd Ivy Small Cap Growth E275.94K1.28%-
Macquarie Small Cap Growth C275.94K1.27%-

Recent Insider Transactions

DateNameRoleActivityValue
May 15, 2025Gutwerg Ori SVP, GENERICSSell$52.92K
May 14, 2025Mutz Christopher HEAD OF RARE DISEASESell$241.80K
May 13, 2025Cook Meredith SR. VP, GENERAL COUNSEL & SEC.Sell$24.88K
May 09, 2025Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPSSell$53.78K
Apr 14, 2025Cook Meredith SR. VP, GENERAL COUNSEL & SEC.Sell$27.58K

Insider Transactions Trends

DateBuySell
2025 Q2-5
2025 Q1-8
2024 Q4-8
2024 Q3-8
2024 Q2-24

ANIP Ownership FAQ

Who Owns ANI Pharmaceuticals?

ANI Pharmaceuticals shareholders are primarily institutional investors at 101.87%, followed by 10.98% insiders and -12.85% retail investors. The average institutional ownership in ANI Pharmaceuticals's industry, Specialty & Generic Drug Manufacturers Stocks, is 2774.71%, which ANI Pharmaceuticals falls below.

Who owns the most shares of ANI Pharmaceuticals?

ANI Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (2.74M shares, 14.11%), Blackrock (2.66M shares, 13.91%), and Vanguard group (1.31M shares, 6.77%). Together, they hold 34.80% of ANI Pharmaceuticals’s total shares outstanding.

Does Blackrock own ANI Pharmaceuticals?

Yes, BlackRock owns 13.91% of ANI Pharmaceuticals, totaling 2.66M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 169.17M$. In the last quarter, BlackRock increased its holdings by 125.17K shares, a 4.94% change.

Who is ANI Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Global alpha capital management is ANI Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 2.51% of its assets in 624.55K ANI Pharmaceuticals shares, valued at 34.53M$.

Who is the top mutual fund holder of ANI Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of ANI Pharmaceuticals shares, with 4.61% of its total shares outstanding invested in 997.35K ANI Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools